Genitourinary Cancers | Topics

Management of Testicular Germ Cell Tumor With Somatic-Type Malignancy
June 15, 2022

In this installment of Clinical Quandaries, Bendu Konneh, BS, and colleagues present a case of a 21-year-old male with a 4-month history of progressive swelling in the right testicle.

Unmet Needs and the Future of Kidney Cancer
June 02, 2022

Drs Tom Powles and Brian Shimkus muse on the unmet needs of kidney cancers and treatments on the horizon to look forward to.

Treatment Approaches for Good Risk Patients with Renal Cell Carcinoma
June 02, 2022

A discussion on how patient risk groups play into deciding on the appropriate treatment for renal cell carcinoma.

Clinical Pearls on Recent Advances and the Future of Treatment in RCC
June 02, 2022

Mehmet Asim Bilen, MD, summarizes recent advances in metastatic RCC and looks towards the future of the field.

Reflections on Novel Targets and Emerging Regimens for RCC
June 02, 2022

Arnab Basu, MD, MPH, FACP, weighs in on novel therapeutic targets and emerging regimens that may further improve kidney cancer outcomes.

Choosing a Combination Therapy for Renal Cell Carcinoma Before and After CLEAR Data
May 26, 2022

Brian Shimkus, MD, discusses how he chose between RCC combination therapies before CLEAR trial data, and how the data influences his decisions now.

Dose Reductions and Treatment Breaks on Lenvatinib Therapy
May 26, 2022

Dr Brian Shimkus describes how he doses lenvatinib for renal cell carcinoma treatment.

The Importance of Team-Based Management and Patient Communication
May 25, 2022

Robert Alter, MD, comments on the importance of team-based care and frequent, timely communication in managing patients with RCC.

Clinical Pearls on Tailoring Dosing Strategies in Metastatic Kidney Cancer
May 25, 2022

David Aggen, MD, PhD, identifies dosing strategies that may maximize treatment efficacy while minimizing toxicity in patients with kidney cancer.

Choosing Therapies for Patients with Advanced Renal Cell Carcinoma
May 19, 2022

A physician explains why he doesn’t believe there is a “typical” patient and why advanced RCC therapies must be tailored to each case.